期刊
BRITISH JOURNAL OF CANCER
卷 101, 期 12, 页码 2048-2054出版社
SPRINGERNATURE
DOI: 10.1038/sj.bjc.6605416
关键词
BRCA1; BRCA2; ERCC4; breast cancer
类别
资金
- Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom
- Cancer Research UK [11022, 10118] Funding Source: researchfish
- Cancer Research UK [10118, 11022, C1287/A10118, C5047/A8385, C1287/A8874, C8197/A10123] Funding Source: Medline
- CIHR Funding Source: Medline
- Intramural NIH HHS [NIH0014262027] Funding Source: Medline
- NCI NIH HHS [U01 CA069446, R01 CA074415, N02CP11019, U01 CA069638, P50CA116201, U01 CA69417, U01 CA069467, RFA-CA-06-503, N02-CP-11019-50, CA122340, CA 27469, U01 CA069398, U10 CA027469, CA116167, U01 CA069631, U10 CA037517, U01 CA69398, N02CP65504, U01 CA69638, U01 CA69446, CA 37517, U01 CA69631, U01 CA69467, R01 CA122340, P50 CA116201, R01 CA116167, R01 CA128978, U01 CA116167, CA74415, CA128978, U01 CA069417] Funding Source: Medline
BACKGROUND: In this study we aimed to evaluate the role of a SNP in intron I of the ERCC4 gene (rs744154), previously reported to be associated with a reduced risk of breast cancer in the general population, as a breast cancer risk modifier in BRCA1 and BRCA2 mutation carriers. METHODS: We have genotyped rs744154 in 9408 BRCA1 and 5632 BRCA2 mutation carriers from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) and assessed its association with breast cancer risk using a retrospective weighted cohort approach. RESULTS: We found no evidence of association with breast cancer risk for BRCA1 (per-allele HR: 0.98, 95% CI: 0.93-1.04, P = 0.5) or BRCA2 (per-allele HR: 0.97, 95% CI: 0.89-1.06, P = 0.5) mutation carriers. CONCLUSION: This SNP is not a significant modifier of breast cancer risk for mutation carriers, though weak associations cannot be ruled out. British Journal of Cancer (2009) 101, 2048-2054. doi: 10.1038/sj.bjc.6605416 www.bjcancer.com Published online 17 November 2009 (C) 2009 Cancer Research UK
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据